Avid Bioservices Inc (CDMO)

[sulaco]

Bristol-Myers Downgraded On Lung-Cancer Drug Data


Doesn't anybody see what this article means???
Of course, Yervoy and nivolumab don't work together...they're BOTH downstream inhibitors. With toxic side effects GALORE. Discontinuation of therapy. Failure. BMY is going to have to combine their drugs with the drug of "another company." They've already spent BILLIONS on these drugs, people.

Enter Peregrine.

Enter Bavi.

For all those long-time posters here who have done their DD, these BMY results make perfect sense. Downstream-downstream inhibition just ain't gonna cut it, people. You need an UPSTREAM-downstream combination.

The science is all there.

It's funny, but BMY's failure proves Bavi's value all the more.

Check the last sentence of the article quoted here.


GLTAL!

Best,

Joe

By AMY REEVES, INVESTOR'S BUSINESS DAILY


Posted 05/15/2014 12:24 PM ET
Bristol-Myers Squibb (BMY) was down more than 6% on the stock market today after the company's latest cancer-drug data moved one analyst to downgrade the stock, though others saw little that was unexpected.

Late Wednesday, the abstracts for various presentations at the upcoming American Society for Clinical Oncology (ASCO) meeting went online, including phase-two data on Bristol's much-anticipated immuno-oncology candidate nivolumab in combination with the company's already marketed Yervoy. In non-small-cell lung cancer, the response rate (i.e. tumor shrinkage) was 22%, while the rate of adverse events was 48%, with many of the latter obliged to discontinue treatment.

"The future of this combo is uncertain, in our view," wrote BMO Capital Markets analyst Alex Arfaei in a note Thursday. "Similarly, the addition of (Roche chemotherapy agent) Tarceva to nivo(lumab) doesn't seem to add much, and the additional benefit of combining nivo with chemo does not seem worth the added toxicity."


Arfaei also was underwhelmed by the nivolumab-Yervoy data on kidney cancer , which was better — but not better than nivolumab had done with other agents. This finding is significant because Bristol stands to gain a lot more in sales if it can sell nivolumab in combination with its own drug rather than ANOTHER company's.[/quote]